Medicus Pharma Reports 73% Clearance in Skin Cancer Trial With Microneedle TechMedicus Commercial2

Medicus Pharma (NASDAQ: MDCX) is advancing next-generation therapies aimed at transforming treatment for serious diseases. The company’s Phase 2 SKN-JCT-003 clinical trial delivered promising results, showing up to 73% clinical clearance in patients with basal cell carcinoma using its innovative microneedle drug delivery platform.

By combining precision delivery with improved patient outcomes, Medicus is positioning its technology as a potential breakthrough in dermatologic oncology. The company continues to expand its clinical pipeline while working to redefine standards of care through minimally invasive, targeted treatments.

#MedicusPharma
#MDCX
#Biotech
#ClinicalTrials
#SkinCancer
#BasalCellCarcinoma
#DrugDelivery
#Microneedle
#HealthcareInnovation
#MedicalResearch
#Oncology
#Pharmaceuticals
#BiotechInvesting
#LifeSciences
#Innovation